Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

MPLT - MapLight Therapeutics, Inc. So'nggi... | Finranks

Home

MPLT

M

MapLight Therapeutics, Inc. (MPLT)

NMS – Real vaqt narxi. Valyuta: USD

18.55

-0.68 (-3.54%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

18.55

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:04 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

MapLight Therapeutics to Participate in Upcoming Investor Conferences

MapLight Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL) Date: Tuesday, March 10th Format: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL) Date: Wednesday, March 11th Format: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS Forum Date: Wednesday, March 18th Format: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company's website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate.

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. “2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics.

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

In the past week or so, beneficial owners took advantage of MapLight Therapeutics Inc.

Videolar

No Data

There is no data to display

Press-relizlar

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate.